According to the International Forum for the Study of Itch (IFSI), chronic pruritus can be classified into three categories. The etiological classification of pruritus on primarily non-lesional (IFSI II) skin can be challenging, particularly as many patients with internal medicine conditions suffer from accompanying pruritic symptoms. Practical guidance for a structured approach and a current overview of pathophysiological insights as well as topical and systemic therapeutic options are provided by the recently updated European guideline by interdisciplinary pruritus experts, which contains numerous evidence-based recommendations.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
- Bezafibrate
- biliary tract diseases
- Bylvay
- chronic pruritus
- Difelikefalin
- European guideline
- evidence-based recommendations
- gabapentin
- IFSI
- IFSI II
- internal medicine conditions
- International Forum for the Study of Itch
- Kidneys
- Liver
- Montelukast
- Nalbuphin
- Naltrexone
- Odevixibat
- pruritus experts
- pruritus on primarily non-lesional
- Sertraline
You May Also Like
- Myasthenia gravis: immunomodulatory therapies for long-term treatment
Expanded Possibilities Thanks to Innovative Classes of Active Ingredients
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Interstitial Lung Diseases
Update on Idiopathic Pulmonary Fibrosis
- Ischemic stroke: Are smaller or larger brain arteries affected?
Recent study findings on intravenous lysis therapy with fibrinolytic agents
- Interview
“On par with the gold standards for trauma”
- Psychology: Emotional Freedom Techniques (EFT)
Emotional Healing Through Tapping
- Systemic Lupus (SLE): What Does the Diagnosis and Treatment Toolbox Have to Offer?
Treat-to-Target – Consensus Recommendations for GC Tapering and the Use of DMARDs
- Interstitial Lung Diseases